Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darbepoetin Alpha +/- G-CSF vs Best Supportive Care in Low-Risk MDS
NCT00234143Phase 3Unknown
- Sponsor
- St Bartholomew's Hospital
- Start
- Oct 2004
- Modality
- Erythropoietins, Colony Stimulating Factors
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of darbepoetin alfa in myelodysplastic syndrome (MDS) (3 arms), sponsored by St Bartholomew's Hospital. Primary endpoint: Quality of Life at 52 weeks. Status: unknown.
02
Drugs
darbepoetin alfa
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00234143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00234143.